Skip to main content
Clinical Trials/NCT00658905
NCT00658905CompletedPhase 2

A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Infant Formula Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age

Swedish Orphan Biovitrum6 sites in 1 country33 target enrollmentStarted: April 2008Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
33
Locations
6
Primary Endpoint
Coefficient of Fat Absorption in stool

Study Overview

Brief Summary

The purpose of this study is to evaluate the efficacy in preterm infants following treatment with BSSL when administered in infant formula.

Detailed Description

In this double-blind crossover study, patients will be randomized to receive infant formula including BSSL or infant formula without BSSL for the first 7 days. After a wash-out period of 2 days the patients will "crossover" to the other treatment regimen and receive an additional 7 days treatment. The primary efficacy measurements will be made by collecting stool during the last three days of each treatment period.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
— to 32 Weeks (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Preterm infants
  • less than or equal to 32 weeks of gestational age
  • appropriate for gestational age
  • enterally fed with infant formula

Exclusion Criteria

  • Not provided

Arms & Interventions

rhBSSL

Active Comparator

Intervention: rhBSSL (Drug)

Placebo

Placebo Comparator

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Coefficient of Fat Absorption in stool

Time Frame: Stool collected for a 72-hour period during the final 3 days of each treatment period

Secondary Outcomes

  • Change in length and body weight between the start and end of each treatment period(Baseline and after one week of treatment)

Investigators

Sponsor
Swedish Orphan Biovitrum
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (6)

Loading locations...

Similar Trials